Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

microRNA-139-5p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer

Authors: Lijing Zhang, Yujuan Dong, Nana Zhu, Ho Tsoi, Zengren Zhao, Chung Wah Wu, Kunning Wang, Shu Zheng, Simon SM Ng, Francis KL Chan, Joseph JY Sung, Jun Yu

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Background

miR-139-5p was identified to be significantly down-regulated in colon tumor tissues by miRNA array. We aimed to clarify its biological function, molecular mechanisms and direct target gene in colorectal cancer (CRC).

Methods

The biological function of miR-139-5p was examined by cell growth, cell cycle and apoptosis analysis in vitro and in vivo. miR-139-5p target gene and signaling pathway was identified by luciferase activity assay and western blot.

Results

miR-139-5p was significantly down-regulated in primary tumor tissues (P < 0.0001). Ectopic expression of miR-139-5p in colon cancer cell lines significantly suppressed cell growth as evidenced by cell viability assay (P < 0.001) and colony formation assay (P < 0.01) and in xenograft tumor growth in nude mice (P < 0.01). miR-139-5p induced apoptosis (P < 0.01), concomitantly with up-regulation of key apoptosis genes including cleaved caspase-8, caspase-3, caspase-7 and PARP. miR-139-5p also caused cell cycle arrest in G0/G1 phase (P < 0.01), with upregulation of key G0/G1 phase regulators p21Cip1/Waf1 and p27Kip1. Moreover, miR-139-5p inhibited cellular migration (P < 0.001) and invasiveness (P < 0.001) through the inhibition of matrix metalloproteinases (MMP)7 and MMP9. Oncogene NOTCH1 was revealed to be a putative target of miR-139-5p, which was inversely correlated with miR-139-5p expression (r = -0.3862, P = 0.0002).

Conclusions

miR-139-5p plays a pivotal role in colon cancer through inhibiting cell proliferation, metastasis, and promoting apoptosis and cell cycle arrest by targeting oncogenic NOTCH1.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127: 2893-2917. 10.1002/ijc.25516.CrossRefPubMed
2.
Sung JJ, Lau JY, Goh KL, Leung WK: Asia Pacific working group on colorectal cancer. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005, 6: 871-876. 10.1016/S1470-2045(05)70422-8.CrossRefPubMed
3.
Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 2006, 6: 857-866. 10.1038/nrc1997.CrossRefPubMed
4.
5.
Deng S, Calin GA, Croce CM, Coukos G, Zhang L: Mechanisms of microRNA deregulation in human cancer. Cell Cycle. 2008, 7: 2643-2646. 10.4161/cc.7.17.6597.CrossRefPubMed
6.
Zhang N, Li X, Wu CW, Dong Y, Cai M, Mok MT, Wang H, Chen J, Ng SS, Chen M, Sung JJ, Yu J: microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis. Oncogene. in press
7.
He X, Dong Y, Wu CW, Zhao Z, Ng SS, Chan FK, Sung JJ, Yu J: MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene. Mol Med. 2013, 18: 1491-1498.PubMed
8.
Dong Y, Zhao J, Wu CW, Zhang L, Liu X, Kang W, Leung WW, Zhang N, Chan FK, Sung JJ, Ng SS, Yu J: Tumor suppressor functions of miR-133a in colorectal cancer. Mol Cancer Res. 2013, 11: 1051-1060. 10.1158/1541-7786.MCR-13-0061.CrossRefPubMed
9.
Wu CW, Ng SC, Dong Y, Tian L, Ng SS, Leung WW, Law WT, Yau TO, Chan FK, Sung JJY, Jun Y: Identification of microRNA-135b in stool as a potential non-invasive biomarker for colorectal cancer and adenoma. Clin Cancer Res. in press
10.
Vu TH, Werb Z: Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 2000, 14: 2123-2133. 10.1101/gad.815400.CrossRefPubMed
11.
Zucker S, Vacirca J: Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 2004, 23: 101-117.CrossRefPubMed
12.
Sawey ET, Johnson JA, Crawford HC: Matrix metalloproteinase 7 controls pancreatic acinar cell transdifferentiation by activating the Notch signaling pathway. Proc Natl Acad Sci U S A. 2007, 104: 19327-19332. 10.1073/pnas.0705953104.PubMedCentralCrossRefPubMed
13.
Pope JL, Bhat AA, Sharma A, Ahmad R, Krishnan M, Washington MK, Beauchamp RD, Singh AB, Dhawan P: Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling. Gut. 2014, 63: 622-634. 10.1136/gutjnl-2012-304241.PubMedCentralCrossRefPubMed
14.
Olaru AV, Selaru FM, Mori Y, Vazquez C, David S, Paun B, Cheng Y, Jin Z, Yang J, Agarwal R, Abraham JM, Dassopoulos T, Harris M, Bayless TM, Kwon J, Harpaz N, Livak F, Meltzer SJ: Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation. Inflamm Bowel Dis. 2011, 17: 221-231. 10.1002/ibd.21359.PubMedCentralCrossRefPubMed
15.
Cekaite L, Rantala JK, Bruun J, Guriby M, Agesen TH, Danielsen SA, Lind GE, Nesbakken A, Kallioniemi O, Lothe RA, Skotheim RI: MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia. 2012, 14: 868-879.PubMedCentralCrossRefPubMed
16.
Chang KH, Miller N, Kheirelseid EA, Lemetre C, Ball GR, Smith MJ, Regan M, McAnena OJ, Kerin MJ: MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. Int J Colorectal Dis. 2011, 26: 1415-1422. 10.1007/s00384-011-1279-4.CrossRefPubMed
17.
Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin P, Lu Y, Li Q, Liu J: MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochem Pharmacol. 2012, 84: 320-330. 10.1016/j.bcp.2012.04.017.CrossRefPubMed
18.
Schepeler T, Holm A, Halvey P, Nordentoft I, Lamy P, Riising EM, Christensen LL, Thorsen K, Liebler DC, Helin K, Ørntoft TF, Andersen CL: Attenuation of the beta-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes. Oncogene. 2012, 31: 2750-2760. 10.1038/onc.2011.453.CrossRefPubMed
19.
Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, Wang Y: Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 2009, 24: 652-657. 10.1111/j.1440-1746.2008.05666.x.CrossRefPubMed
20.
Hiroki E, Akahira J, Suzuki F, Nagase S, Ito K, Suzuki T, Sasano H, Yaegashi N: Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci. 2010, 101: 241-249. 10.1111/j.1349-7006.2009.01385.x.CrossRefPubMed
21.
Wong CC, Wong CM, Tung EK, Au SL, Lee JM, Poon RT, Man K, Ng IO: The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology. 2011, 140: 322-331. 10.1053/j.gastro.2010.10.006.CrossRefPubMed
22.
Watanabe K, Sunohara M, Amano Y, Ishikawa R, Ichinose J, Nakajima J, Fukayama M, Yatomi Y, Nagase T, Ohishi N, Takai D: Histone methylation-mediated silencing of mir-139 enhances an aggressive phenotype of non-small cell lung cancer [abstract]. Clin Cancer Res. 2014, 20: B28-B28. 10.1158/1078-0432.CCR-13-0122. doi: 10.1158/1078-0432.14AACRIASLC-B28CrossRef
23.
Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, Ng IO, Wong CM: Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology. 2012, 56: 622-631. 10.1002/hep.25679.CrossRefPubMed
24.
Bao W, Fu HJ, Xie QS, Wang L, Zhang R, Guo ZY, Zhao J, Meng YL, Ren XL, Wang T, Li Q, Jin BQ, Yao LB, Wang RA, Fan DM, Chen SY, Jia LT, Yang AG: HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology. 2011, 141: 2076-2087. 10.1053/j.gastro.2011.08.050.CrossRefPubMed
25.
Krishnan K, Steptoe AL, Martin HC, Pattabiraman DR, Nones K, Waddell N, Mariasegaram M, Simpson PT, Lakhani SR, Vlassov A, Grimmond SM, Cloonan N: miR-139-5p is a regulator of metastatic pathways in breast cancer. RNA. 2013, 19: 1767-1780. 10.1261/rna.042143.113.PubMedCentralCrossRefPubMed
26.
Tokino T, Nakamura Y: The role of p53-target genes in human cancer. Crit Rev Oncol Hemat. 2000, 33: 1-6. 10.1016/S1040-8428(99)00051-7.CrossRef
27.
Cheng WL, Lin TY, Tseng YH, Chu FH, Chueh PJ, Kuo YH, Wang SY: Inhibitory effect of human breast cancer cell proliferation via p21-mediated G(1) cell cycle arrest by Araliadiol isolated from Aralia cordata Thunb. Planta Med. 2011, 77: 164-168. 10.1055/s-0030-1250177.CrossRefPubMed
28.
Broude EV, Swift ME, Vivo C, Chang BD, Davis BM, Kalurupalle S, Blagosklonny MV, Roninson IB: p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation. Oncogene. 2007, 26: 6954-6958. 10.1038/sj.onc.1210516.CrossRefPubMed
29.
Mitrea DM, Yoon MK, Ou L, Kriwacki RW: Disorder-function relationships for the cell cycle regulatory proteins p21 and p27. Biol Chem. 2012, 393: 259-274.CrossRefPubMed
30.
Johnstone RW, Frew AJ, Smyth MJ: The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 2008, 8: 782-798. 10.1038/nrc2465.CrossRefPubMed
31.
32.
Holoch PA, Griffith TS: TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol. 2009, 625: 63-72. 10.1016/j.ejphar.2009.06.066.PubMedCentralCrossRefPubMed
33.
Schutze S, Tchikov V, Schneider-Brachert W: Regulation of TNFR1 and CD95 signalling by receptor compartmentalization. Nat Rev Mol Cell Biol. 2008, 9: 655-662. 10.1038/nrm2430.CrossRefPubMed
34.
Witty JP, McDonnell S, Newell KJ, Cannon P, Navre M, Tressler RJ, Matrisian LM: Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res. 1994, 54: 4805-4812.PubMed
35.
Yamamoto H, Itoh F, Hinoda Y, Imai K: Suppression of matrilysin inhibits colon cancer cell invasion in vitro. Int J Cancer. 1995, 61: 218-222. 10.1002/ijc.2910610213.CrossRefPubMed
36.
van Kempen LC, Coussens LM: MMP9 potentiates pulmonary metastasis formation. Cancer Cell. 2002, 2: 251-252. 10.1016/S1535-6108(02)00157-5.CrossRefPubMed
37.
Guo H, Hu X, Ge S, Qian G, Zhang J: Regulation of RAP1B by miR-139 suppresses human colorectal carcinoma cell proliferation. Int J Biochem Cell Biol. 2012, 44: 1465-1472. 10.1016/j.biocel.2012.05.015.CrossRefPubMed
38.
Qiao L, Wong BC: Role of Notch signaling in colorectal cancer. Carcinogenesis. 2009, 30: 1979-1986. 10.1093/carcin/bgp236.CrossRefPubMed
39.
Riccio O, van Gijn ME, Bezdek AC, Pellegrinet L, van Es JH, Zimber-Strobl U, Strobl LJ, Honjo T, Clevers H, Radtke F: Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep. 2008, 9: 377-383. 10.1038/embor.2008.7.PubMedCentralCrossRefPubMed
40.
Zhang X, Chen T, Zhang J, Mao Q, Li S, Xiong W, Qiu Y, Xie Q, Ge J: Notch1 promotes glioma cell migration and invasion by stimulating β-catenin and NF-κB signaling via AKT activation. Cancer Sci. 2012, 103: 181-190. 10.1111/j.1349-7006.2011.02154.x.CrossRefPubMed
41.
Sarmento LM, Huang H, Limon A, Gordon W, Fernandes J, Tavares MJ, Miele L, Cardoso AA, Classon M, Carlesso N: Notch1 modulates timing of G1-S progression by inducing SKP2 transcription and p27 Kip1 degradation. J Exp Med. 2005, 202: 157-168. 10.1084/jem.20050559.PubMedCentralCrossRefPubMed
42.
Bu P, Chen KY, Chen JH, Wang L, Walters J, Shin YJ, Goerger JP, Sun J, Witherspoon M, Rakhilin N, Li J, Yang H, Milsom J, Lee S, Zipfel W, Jin MM, Gümüş ZH, Lipkin SM, Shen X: A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells. Cell Stem Cell. 2013, 12: 602-615. 10.1016/j.stem.2013.03.002.PubMedCentralCrossRefPubMed
43.
Sureban SM, May R, Mondalek FG, Qu D, Ponnurangam S, Pantazis P, Anant S, Ramanujam RP, Houchen CW: Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. J Nanobiotechnology. 2011, 9: 40-10.1186/1477-3155-9-40.PubMedCentralCrossRefPubMed
44.
Ning L, Wentworth L, Chen H, Weber SM: Down-regulation of Notch1 signaling inhibits tumor growth in human hepatocellular carcinoma. Am J Transl Res. 2009, 1: 358-366.PubMedCentralPubMed
45.
Tanaka M, Setoguchi T, Hirotsu M, Gao H, Sasaki H, Matsunoshita Y, Komiya S: Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer. 2009, 100: 1957-1965. 10.1038/sj.bjc.6605060.PubMedCentralCrossRefPubMed
46.
Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM, Li Y, Nelson RA, Mu B, Onami SH, Wu JJ, Ruel NH, Wilczynski SP, Gao H, Covarrubias M, Figlin RA, Weiss LM, Wu H: Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One. 2012, 7: e35661-10.1371/journal.pone.0035661.PubMedCentralCrossRefPubMed
Metadata
Title
microRNA-139-5p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer
Authors
Lijing Zhang
Yujuan Dong
Nana Zhu
Ho Tsoi
Zengren Zhao
Chung Wah Wu
Kunning Wang
Shu Zheng
Simon SM Ng
Francis KL Chan
Joseph JY Sung
Jun Yu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-124

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue

Research

microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer

Research

Inhibition of G9a induces DUSP4-dependent autophagic cell death in head and neck squamous cell carcinoma

Research

Gold (I) N-heterocyclic carbene complex inhibits mouse melanoma growth by p53 upregulation

Research

Identification and validation of PROM1 and CRTC2 mutations in lung cancer patients

Research

OTUB1 promotes metastasis and serves as a marker of poor prognosis in colorectal cancer

Research

DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits